These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7493140)

  • 1. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
    Andersen TI; Børresen AL
    Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.
    Børresen AL; Hovig E; Smith-Sørensen B; Malkin D; Lystad S; Andersen TI; Nesland JM; Isselbacher KJ; Friend SH
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8405-9. PubMed ID: 1924299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
    Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
    Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
    Valgardsdottir R; Tryggvadottir L; Steinarsdottir M; Olafsdottir K; Jonasdottir S; Jonasson JG; Ogmundsdottir HM; Eyfjörd JE
    APMIS; 1997 Feb; 105(2):121-30. PubMed ID: 9113074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis.
    Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
    Methods Mol Biol; 2005; 291():207-16. PubMed ID: 15502225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE).
    Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
    Methods Mol Biol; 2014; 1105():315-24. PubMed ID: 24623239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
    Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
    Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of TP53 alterations in breast carcinoma.
    Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
    Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
    Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
    Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
    Kringen P; Bergamaschi A; Due EU; Wang Y; Tagliabue E; Nesland JM; Nehman A; Tönisson N; Børresen-Dale AL
    Biotechniques; 2005 Nov; 39(5):755-61. PubMed ID: 16312222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
    Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
    J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
    Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
    Smith-Sørensen B; Gebhardt MC; Kloen P; McIntyre J; Aguilar F; Cerutti P; Børresen AL
    Hum Mutat; 1993; 2(4):274-85. PubMed ID: 8401536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction.
    Bjørheim J; Lystad S; Lindblom A; Kressner U; Westring S; Wahlberg S; Lindmark G; Gaudernack G; Ekstrøm P; Røe J; Thilly WG; Børresen-Dale AL
    Mutat Res; 1998 Jul; 403(1-2):103-12. PubMed ID: 9726011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
    Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
    Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.
    Bukholm IK; Nesland JM; Kåresen R; Jacobsen U; Børresen AL
    J Pathol; 1997 Feb; 181(2):140-5. PubMed ID: 9120716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
    Thorlacius S; Börresen AL; Eyfjörd JE
    Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.